Literature DB >> 12828868

Intramuscular immunization with poliovirus replicons primes for a humoral and cellular immune response to soluble antigen.

Miroslav J Novak1, Zina Moldoveanu, Wen Qiang Huang, Cheryl A Jackson, Matthew T Palmer, Sylvia A McPherson, Casey D Morrow.   

Abstract

Vaccines that stimulate both cellular and humoral immunity will probably be needed to control many infectious diseases. Previously, our laboratory generated a vaccine vector that uses poliovirus genomes (replicons) in which the capsid genes have been replaced by foreign proteins. In the current study, we have evaluated the immune responses induced by immunization using poliovirus replicons encoding green fluorescent protein (GFP). Although intramuscular administration of replicons resulted in GFP expression in the muscle, the levels of anti-GFP antibodies in serum were low compared to those of mice immunized with soluble, recombinant GFP (rGFP). Intramuscular booster immunization with rGFP in animals primed with replicons encoding GFP resulted in production of both serum IgG1 and IgG2a GFP-specific antibodies. The cells isolated from spleens of animals primed with replicons and boosted with rGFP secreted IFN-gamma after in vitro stimulation with rGFP. Intramuscular immunization of animals with a single dose of replicons encoding GFP followed by two intranasal applications of rGFP resulted in serum GFP-specific IgG1 and IgG2a isotypes, consistent with induction of both humoral and cellular responses. The results of this study establish that immunization with replicons followed by boost with soluble antigen, even at a different site, can generate a more diverse immune response compared with immunization regimen using soluble antigen alone. This strategy could be exploited for the development of new vaccine approaches against infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828868     DOI: 10.1089/088282403322017901

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  2 in total

1.  Immunization with non-replicating E. coli minicells delivering both protein antigen and DNA protects mice from lethal challenge with lymphocytic choriomeningitis virus.

Authors:  Matthew J Giacalone; Juan C Zapata; Neil L Berkley; Roger A Sabbadini; Yen-Lin Chu; Maria S Salvato; Kathleen L McGuire
Journal:  Vaccine       Date:  2006-12-26       Impact factor: 3.641

2.  Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery.

Authors:  Matthew J Giacalone; Roger A Sabbadini; Amy L Chambers; Sabitha Pillai; Neil L Berkley; Mark W Surber; Kathleen L McGuire
Journal:  Vaccine       Date:  2006-05-09       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.